Pulse Biosciences Inc Stock Price, News & Analysis

Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced the preliminary results of its rights offering, which concluded on June 26, 2024. The offering, oversubscribed by 138%, is expected to generate $60 million in immediate gross proceeds, with potential additional proceeds of up to $66 million from warrant exercises. Each Unit in the $10.00 per Unit offering included one share of common stock and two warrants, with warrants exercisable at $11.00 per share and redeemable under certain conditions. Over 800 accounts participated, including the Company's Executive Chairman, Robert Duggan. The final proceeds and securities distribution will be confirmed upon the closing of the offering.

Pulse Biosciences has commenced a rights offering of up to $60 million in units. Each unit comprises one share of common stock and two warrants to purchase additional shares. The subscription rights, distributed to holders as of May 31, 2024, expire on June 26, 2024. The units are priced at the lesser of $10 per unit or the volume-weighted average price over ten trading days up to the expiration date. The warrants are exercisable immediately and valid for five years. The rights offering includes an over-subscription option, allowing shareholders to buy extra units if available. This offering adheres to the company's SEC registration currently in effect.

Pulse Biosciences announced an updated record date for its rights offering to raise up to $60 million. The new record date is May 31, 2024, replacing the original May 16, 2024. This offering allows stockholders to purchase up to 6 million units at a price of either $10 or the volume weighted average price over the ten days preceding the expiration date, June 26, 2024. Each unit includes one share of Common Stock and two warrants. If fully subscribed, the offering will provide gross proceeds of $60 million minus expenses. The Registration Statement is effective, and all details can be found on the SEC’s website.

Pulse Biosciences' CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology will be featured in several presentations at the Heart Rhythm Society 2024 Annual Meeting in Boston, MA, from May 16-19. The technology will be highlighted in six presentations and abstracts, including a live case presentation.

The preclinical and initial clinical results for CellFX nsPFA have shown promise, particularly in treating atrial fibrillation. The presentations will cover various aspects of the technology, including preclinical evaluations, first-in-human experiences, and novel catheter designs.

Prominent sessions include a live case demonstrating PVI+ with nsPFA, a presentation on the biophysical insights of novel ablation technologies, and multiple poster sessions on preclinical and clinical assessments of the technology.

Pulse Biosciences (Nasdaq: PLSE) has appointed Burke T. Barrett as President and CEO, replacing Kevin Danahy, who will become Chief Commercial Officer. Barrett brings over 35 years of experience in the medical device sector, including leadership roles at CardioFocus, Cyberkinetics, and Cyberonics. The leadership changes aim to support the company’s next growth phase, particularly the launch of its FDA-cleared CellFX nsPFA Percutaneous Electrode System. Barrett has been granted options to purchase 1.4 million shares at $7.45 per share, subject to vesting over four years and market capitalization milestones.

Pulse Biosciences, Inc. (PLSE) announced the first U.S. procedure using the CellFX nsPFA Percutaneous Electrode System after FDA clearance. The successful case marks a significant milestone in the company's pilot program, showing promising results in treating soft tissue without damaging noncellular structures. The innovative technology aims to revolutionize patient care with minimal pain and no need for general anesthesia. The company is looking forward to expanding the procedure's usage in 2024, following successful trials in Italy.

Pulse Biosciences, Inc. reported business updates and financial results for the first quarter of 2024, highlighting FDA clearance for CellFX nsPFA Percutaneous Electrode, ongoing dialogue with the FDA for CellFX nsPFA Cardiac Clamp, and submission of a feasibility study for CellFX nsPFA 360° Cardiac Catheter. Additionally, the company announced a planned rights offering of up to $60 million to fund growth plans, with a change in record date. Financially, GAAP costs and expenses increased driven by non-cash stock-based compensation, resulting in a net loss of ($10.1) million for Q1 2024. Cash and cash equivalents totaled $34.9 million as of March 31, 2024.

Pulse Biosciences, Inc. (PLSE) announced a rights offering for up to $60 million, with a record date set for May 16, 2024. The offering allows common stockholders to purchase Units at $10 or the market price. Each Unit includes one share of common stock and two warrants. The offering includes an over-subscription right. The Registration Statement with the SEC has been filed but is not yet effective.